BINOSTO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BINOSTO (BINOSTO).
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone matrix and inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
| Metabolism | Not metabolized; excreted unchanged primarily via renal clearance. |
| Excretion | Renal: 50% excreted unchanged in urine; fecal: 20% as unabsorbed drug; biliary: negligible |
| Half-life | Terminal elimination half-life is approximately 10 hours; clinical context: supports once-weekly dosing for osteoporosis |
| Protein binding | Approximately 24% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | Vd: 0.2 L/kg; clinical meaning: low distribution, confined primarily to plasma and bone surface |
| Bioavailability | Oral: 0.7% (range 0.4–1.0%) when taken with plain water under fasting conditions |
| Onset of Action | Oral: 1–2 hours for suppression of bone resorption markers |
| Duration of Action | Duration of action: 1 week for bone turnover suppression; clinical notes: administered weekly due to prolonged binding to bone hydroxyapatite |
70 mg orally once weekly
| Dosage form | TABLET, EFFERVESCENT |
| Renal impairment | CrCl <35 mL/min: not recommended; CrCl 35-60 mL/min: no adjustment needed; CrCl >60 mL/min: no adjustment needed |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment |
| Pediatric use | Not approved for pediatric use (safety and efficacy not established) |
| Geriatric use | No specific dose adjustment; consider renal function and comorbidities |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BINOSTO (BINOSTO).
| Breastfeeding | Alendronate is excreted into human breast milk in low amounts; M/P ratio unknown. Due to potential for bone growth suppression in the infant, breastfeeding is not recommended during therapy. Consider alternative treatments if breastfeeding is necessary. |
| Teratogenic Risk | Bisphosphonates, including BINOSTO (alendronate), are not recommended during pregnancy. First trimester: Limited data suggest no significant increase in major malformations, but risk cannot be excluded due to small sample sizes. Second and third trimesters: Potential risk of fetal skeletal abnormalities due to calcium homeostasis disruption. Alendronate is classified as FDA Pregnancy Category C. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypocalcemia","Inability to stand or sit upright for at least 30 minutes","Severe renal impairment (CrCl <30 mL/min)","Esophageal abnormalities that delay esophageal emptying"]
| Precautions | ["Risk of atypical femur fractures","Osteonecrosis of the jaw","Severe musculoskeletal pain","Hypocalcemia","Renal impairment","Esophageal irritation or ulceration if not taken properly"] |
| Food/Dietary | Food, beverages (including mineral water, coffee, orange juice, and milk), and other oral medications significantly reduce absorption. Must be taken with plain water only on an empty stomach. Avoid high-calcium foods (e.g., dairy, fortified juices) within 30 minutes of dosing. Separate from calcium supplements, antacids, and iron supplements by at least 30 minutes. |
Loading safety data…
| Fetal Monitoring | If unintentional exposure occurs during pregnancy, monitor maternal serum calcium, phosphate, and bone turnover markers. Fetal monitoring via ultrasound for skeletal development if exposure in second/third trimester. No specific monitoring required in standard use. |
| Fertility Effects | In animal studies, alendronate caused delayed ovulation and decreased implantation at high doses. Human data are limited; no significant effects on fertility reported in clinical studies. However, caution is advised in women of reproductive potential due to long half-life in bone. |
| Clinical Pearls | Binosto (alendronate sodium effervescent tablet) is a bisphosphonate for osteoporosis. Administer immediately after dissolving in at least 4 oz of room temperature water; do not chew or suck tablets. Give at least 30 minutes before first food, beverage, or other medication of the day to ensure absorption and reduce esophageal irritation. Monitor for hypocalcemia and renal function (CrCl <35 mL/min contraindicated). Discontinue if severe bone, joint, or muscle pain occurs. Consider drug holidays after 5 years for low-risk patients. |
| Patient Advice | Take Binosto first thing in the morning on an empty stomach with a full glass of plain water (4-6 oz). Do not use mineral water or other beverages. · Wait at least 30 minutes after taking the tablet before eating, drinking, or taking any other medications. · Dissolve the tablet completely in water before drinking. Do not chew or swallow the tablet whole. · Stay upright (sitting or standing) for at least 30 minutes after taking to prevent esophageal irritation. · Swallow quickly after dissolution to avoid incomplete dosing. · Report any difficulty swallowing, pain when swallowing, retrosternal pain, or new/worsening heartburn. · Take calcium and vitamin D supplements as directed, but separate from Binosto by at least 30 minutes. · Rapid weight loss or prolonged immobility may increase risk of adverse effects. · Annual dental exams and good oral hygiene are recommended; report any jaw pain or delayed healing after dental procedures. · Do not double the dose if missed; skip it and take the next day's dose as usual. |